http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 14 Jul 2026 03:32:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html <p>Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.</p> <p>Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.</p> <p>Following the share issuance, Fortress is expected to hold approximately 60.52% of http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html Tue, 14 Jul 2026 03:32:18 -0400 A.32501476 A.33754629 CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html <p>Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.</p> <p>Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.</p> <p>Following the share issuance, Fortress is expected to hold approximately 60.52% of http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html Tue, 14 Jul 2026 03:32:18 -0400 A.32501476 A.33754629 CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html <p>Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.</p> <p>Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.</p> <p>Following the share issuance, Fortress is expected to hold approximately 60.52% of http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html Tue, 14 Jul 2026 03:32:18 -0400 A.32501476 A.33754629 CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html <p>Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.</p> <p>Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.</p> <p>Following the share issuance, Fortress is expected to hold approximately 60.52% of http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html Tue, 14 Jul 2026 03:32:18 -0400 A.32501476 A.33754629 CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html <p>Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.</p> <p>Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.</p> <p>Following the share issuance, Fortress is expected to hold approximately 60.52% of http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html Tue, 14 Jul 2026 03:32:18 -0400 A.32501476 A.33754629 CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html <p>Celyad Oncology SA (Euronext: CYAD) has entered into a subscription agreement for a €500,000 private placement with CFIP CLYD (UK) Limited, an affiliate of Fortress Investment Group LLC, according to a company statement.</p> <p>Under the terms of the agreement, Fortress will receive 2,500,000 newly issued ordinary shares at €0.20 per share, representing a 15% discount to the volume-weighted average price of Celyad Oncology shares on Euronext Brussels over the preceding ten trading days. The transaction is expected to close on or around July 15, 2026, subject to customary closing conditions.</p> <p>Following the share issuance, Fortress is expected to hold approximately 60.52% of http://www.streetinsider.com/Equity+Offerings/Celyad+Oncology+raises+%E2%82%AC500%2C000+via+Fortress+private+placement/26763713.html Tue, 14 Jul 2026 03:32:18 -0400 A.32501476 A.33754629 CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> <i>Celyad Oncology SA</i> (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announced that it has entered into a subscription agreement for a private placement financing (the “Transaction”) with an affiliate of Fortress Investment Group LLC (“Fortress Investment Group”). </p><p> Under the terms of the subscription agreement, CFIP CLYD (UK) Limited (“Fortress”) will subscribe to a capital increase for an aggregate amount of €500,000 in exchange for 2,500,000 newly issued ordinary shares of Celyad Oncology. The shares will be issued at a subscription price of €0.20 per share, which represents a 15% discount to the volume-weighted http://www.streetinsider.com/Business+Wire/Celyad+Oncology+Announces+%E2%82%AC500%2C000+Private+Placement/26763712.html Tue, 14 Jul 2026 03:32:00 -0400 A.32501476 A.33754629 CYAD CYAD CYAD O.00832386 O.03284122 O.04880301 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Reports+Full+Year+2025+Financial+Results+and+Business+Highlights/26265040.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update. </p><p> <b>2025 business and operational highlights</b> </p><ul class="bwlistdisc"> <li> The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies; </li> <li> The Company discontinued its R&amp;D activities and sold its research facility for €3 million. </li> </ul><p> <b>Full year 2025 financial review</b> </p><p> As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million. </p><p> The Company projects that its existing cash and cash equivalents should be sufficient http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Reports+Full+Year+2025+Financial+Results+and+Business+Highlights/26265040.html Thu, 02 Apr 2026 13:00:00 -0400 CYAD CYAD CYAD O.03284122 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Reports+Full+Year+2025+Financial+Results+and+Business+Highlights/26265040.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update. </p><p> <b>2025 business and operational highlights</b> </p><ul class="bwlistdisc"> <li> The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies; </li> <li> The Company discontinued its R&amp;D activities and sold its research facility for €3 million. </li> </ul><p> <b>Full year 2025 financial review</b> </p><p> As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million. </p><p> The Company projects that its existing cash and cash equivalents should be sufficient http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Reports+Full+Year+2025+Financial+Results+and+Business+Highlights/26265040.html Thu, 02 Apr 2026 13:00:00 -0400 CYAD CYAD CYAD O.03284122 http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Reports+Full+Year+2025+Financial+Results+and+Business+Highlights/26265040.html <p> MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News: </p><p> Celyad Oncology (Euronext: CYAD) (the “Company”), today announces its financial results for the fiscal year ended December 31, 2025, and provides a business update. </p><p> <b>2025 business and operational highlights</b> </p><ul class="bwlistdisc"> <li> The Company remains focused on partnering its intellectual property and has progressed in the discussions with potential partners for selected out-licensing of its technologies; </li> <li> The Company discontinued its R&amp;D activities and sold its research facility for €3 million. </li> </ul><p> <b>Full year 2025 financial review</b> </p><p> As of December 31, 2025, the Company’s Treasury position amounts to €1.7 million. </p><p> The Company projects that its existing cash and cash equivalents should be sufficient http://www.streetinsider.com/Press+Releases/Celyad+Oncology+Reports+Full+Year+2025+Financial+Results+and+Business+Highlights/26265040.html Thu, 02 Apr 2026 13:00:00 -0400 CYAD CYAD CYAD O.03284122